4.6 Article

Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Gastroenterology & Hepatology

Biologics for Inflammatory Bowel Disease and Their Safety Pregnancy: A Systematic Review and Meta-analysis

Ole Haagen Nielsen et al.

Summary: Adverse pregnancy outcomes among pregnant IBD women using biologics are comparable with that of the general population.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Article Gastroenterology & Hepatology

Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero

Emma Flanagan et al.

Summary: Ustekinumab levels remain stable in pregnant women with IBD, with a higher level in infants at delivery and complete clearance within 9 weeks. Infants exposed to ustekinumab in utero should avoid live vaccination before 12 months of age.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Article Gastroenterology & Hepatology

Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease

Uma Mahadevan et al.

Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.

GASTROENTEROLOGY (2021)

Article Gastroenterology & Hepatology

Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study

Mette Julsgaard et al.

Summary: This study investigated the clearance of vedolizumab in newborns after intrauterine exposure, finding rapid clearance and no correlation with infection risk during the first year of life. Continuation of vedolizumab throughout pregnancy was deemed safe.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

Article Gastroenterology & Hepatology

Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study

Katarina Mitrova et al.

Summary: Vedolizumab demonstrates unique placental pharmacokinetics resulting in lower drug levels in cord blood compared to maternal blood at delivery, while ustekinumab shows a placental transfer pattern similar to anti-TNF agents.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)

Article Gastroenterology & Hepatology

Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines

Dawn B. Beaulieu et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)

Article Gastroenterology & Hepatology

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection

Mette Julsgaard et al.

GASTROENTEROLOGY (2016)

Article Gastroenterology & Hepatology

Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study

Martin Bortlik et al.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2013)